Monthly Archives: August 2017

Bimatoprost is currently approved for the listing of two brands, namely Lumigan and Latisse. Lumigan is considered to be the strongest local anti-glaucoma drugs, which was approved by the FDA in 2001 for local ophthalmic preparations. Latisse is the only FDA-approved eyelash hyperplasia in the world. Clinical trials have shown that it can make eyelashes […]

Bimatoprost ophthalmic solutions have been reported to cause changes to pigmented tissue. The changes include increased pigmentation and growth of eyelashes and increased pigmentation of the iris and periorbital tissue (eyelid). The increased iris pigmentation may be permanent.Bimatoprost ophthalmic solution may gradually change eye color, increasing the amount of brown pigment in the iris by […]